Photo from academic.microsoft.com
The ability to design 'biased' drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee… Click to show full abstract
The ability to design 'biased' drugs that selectively activate G protein-coupled receptor (GPCR) signaling pathways beneficial in treating a disease, while limiting their side effects, is of broad significance. Lee et al. move us a step closer to this important goal by identifying structural differences in the β1-adrenoceptor in complex with β-arrestin 1 versus a G protein-mimicking nanobody.
Keywords:
developments biased;
biased signaling;
arresting developments
Journal Title: Trends in pharmacological sciences
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Trends in pharmacological sciences
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!